LivaNova (NASDAQ:LIVN) Rating Increased to Strong-Buy at Baird R W

LivaNova (NASDAQ:LIVN) was upgraded by stock analysts at Baird R W from a “hold” rating to a “strong-buy” rating in a report released on Tuesday, Zacks.com reports.

A number of other equities analysts have also weighed in on the stock. Needham & Company LLC lifted their price objective on shares of LivaNova from $72.00 to $75.00 and gave the company a “buy” rating in a research report on Wednesday, July 31st. Robert W. Baird upgraded shares of LivaNova from a “neutral” rating to an “outperform” rating and raised their target price for the stock from $55.00 to $66.00 in a research note on Tuesday. Finally, Stifel Nicolaus boosted their price target on shares of LivaNova from $70.00 to $72.00 and gave the stock a “buy” rating in a research note on Thursday, July 25th. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $70.80.

LivaNova Price Performance

Shares of NASDAQ:LIVN opened at $51.07 on Tuesday. LivaNova has a one year low of $42.75 and a one year high of $64.47. The stock has a market capitalization of $2.77 billion, a price-to-earnings ratio of -85.12 and a beta of 1.00. The company has a 50-day simple moving average of $48.88 and a 200-day simple moving average of $53.42. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.94 and a current ratio of 3.45.

LivaNova (NASDAQ:LIVN) last issued its quarterly earnings results on Wednesday, July 31st. The company reported $0.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.66 by $0.15. LivaNova had a positive return on equity of 13.77% and a negative net margin of 1.37%. The firm had revenue of $318.60 million for the quarter, compared to analysts’ expectations of $305.05 million. On average, analysts predict that LivaNova will post 2.58 EPS for the current year.

Institutional Trading of LivaNova

A number of institutional investors have recently added to or reduced their stakes in LIVN. Hexagon Capital Partners LLC increased its holdings in LivaNova by 117.8% in the second quarter. Hexagon Capital Partners LLC now owns 684 shares of the company’s stock valued at $37,000 after buying an additional 370 shares in the last quarter. Fifth Third Bancorp raised its holdings in LivaNova by 97.1% during the second quarter. Fifth Third Bancorp now owns 674 shares of the company’s stock worth $37,000 after purchasing an additional 332 shares during the last quarter. Lazard Asset Management LLC acquired a new position in LivaNova during the first quarter worth $84,000. Canada Pension Plan Investment Board purchased a new stake in LivaNova during the second quarter worth $88,000. Finally, Acadian Asset Management LLC acquired a new stake in LivaNova in the first quarter valued at $94,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.